Klinikum der Johann Wolfgang Goethe-Universität
Frankfurt a.M., Hesse, 60590, Germany
NCT Number: NCT01279577
This study will run in centers in Germany, Denmark, Austria, Czech Republic, and Switzerland, only.
This proof-of-concept study aims to evaluate the efficacy of three doses of oral TSO suspension vs. placebo for the induction of remission in Crohn's disease.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Frankfurt a.M., Hesse, 60590, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Major Inclusion Criteria:
Major Exclusion Criteria:
Low dose TSO suspension
Medium dose TSO suspension
High dose TSO suspension
Placebo solution
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Dr. Falk Pharma GmbH
Industry
Double-blind, Randomised, Placebo-controlled, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Three Different Dosages of Oral Trichuris Suis Ova (TSO) Suspension in Active Crohn's Disease
Acronym: TRUST-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03890445
Crohn Disease, Crohn´s Disease
Innsbruck, Austria
View Trial DetailsNCT01417715
Colitis, Colitis, Ulcerative
Erlangen, Germany
View Trial DetailsNCT01417702
Colitis, Colitis, Ulcerative
Erlangen, Germany
View Trial DetailsNCT01860651
Colitis, Colitis, Ulcerative
Hvidovre, Denmark
View Trial Details